Tag Archives: SAGE

SAGE Therapeutics (SAGE) Gets a Hold Rating from H.C. Wainwright

In a report released today, Douglas Tsao from H.C. Wainwright maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $78.00. The company’s shares closed last Monday at $52.01, close to its 52-week low

Ladenburg Thalmann & Co. Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)

Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $52.00. The company’s shares closed last Monday at $52.01, close to its 52-week low of

Analysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (NASDAQ: SAGE) and Radius Health (NASDAQ: RDUS)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on SAGE Therapeutics (SAGE – Research Report) and Radius Health (RDUS – Research Report). SAGE Therapeutics (SAGE) Cowen & Co. analyst Ritu Baral maintained

Analysts Have Conflicting Sentiments on These Healthcare Companies: SAGE Therapeutics (NASDAQ: SAGE), Mesoblast (NASDAQ: MESO) and Co-Diagnostics (NASDAQ: CODX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on SAGE Therapeutics (SAGE – Research Report), Mesoblast (MESO – Research Report) and Co-Diagnostics (CODX – Research Report). SAGE Therapeutics (SAGE) Mizuho Securities analyst Vamil Divan

SAGE Therapeutics (SAGE) Gets a Buy Rating from Oppenheimer

Oppenheimer analyst Jay Olson maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) on January 14 and set a price target of $100.00. The company’s shares closed last Monday at $75.44, close to its 52-week low of $56.50.

The President & CEO of SAGE Therapeutics (NASDAQ: SAGE) is Buying Shares

Yesterday, the President & CEO of SAGE Therapeutics (SAGE – Research Report), Jeffrey Jonas, bought shares of SAGE for $481.5K. This recent transaction increases Jeffrey Jonas’ holding in the company by 15.95% to a total of $3.45 million. In addition